Abstract
CD28 expression and serum levels are significantly increased in patients with SLE than in healthy controls (HC). Until now, there are no studies of proximal promoter polymorphisms of CD28 gene in SLE. Therefore, our objective was to investigate the polymorphisms present in the proximal promoter of CD28 in a group of SLE and HC and to associate the polymorphisms present with the CD28 serum levels of 40 patients and 40 controls. One hundred and seven patients as well as 108 controls matched by age range and genders were included. The 11 ACR criteria were analyzed on the clinical files, and the proximal promoter region of CD28 gene was analyzed by direct sequencing of a 489-basepair fragment. C28 serum levels (sCD28) were measured by ELISA technique in 40 patients and 40 controls. Only two of the eight reported polymorphisms were found, and they correspond to rs35593994 (−372 A/G) and rs56156157 (−145 −/C). The first had a prevalence of 41 and 36% in patients and controls respectively and the second of 1.4% in both groups. None of these polymorphisms were associated with SLE, and the polymorphism −372 A/G was not associated with the clinical features of disease. Likewise, the association with the sCD28 and the genotypes of −372 A/G polymorphism was not significant. The polymorphisms of the proximal promoter of CD28 are not associated with SLE, and the polymorphism −372 A/G is not associated with the diagnostic criteria of SLE or the sCD28.
Similar content being viewed by others
References
Kaneko H, Saito K, Hashimoto H, Yagita H, Okumura K, Azuma M (1996) Preferential elimiantion of CD28+ T cells in systemic lupus erythematosis (SLE) and the relation with activation-induced apoptosis. Clin Exp Immunol 106:218–229
Wong CK, Lit LCW, Tam LS, Li EK, Lam CWK (2005) Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology 44:989–994
Hebbar M, Jeannin P, Magistrelli G, Hatron PY, Hachulla E, Devulder B et al (2004) Detection of circulating soluble CD28 in patients with lupus erythematosus, primary Sjögren syndrome and systemic sclerosis. Clin Exp Immunol 136:388–392
Alvarado C, Alcocer-Varela J, Llorente L, Richaud-Patin Y, Cerbon M, Alarcon-Segovia D (1994) Effect of CD28 antibody on T cells from patients with systemic lupus erythematosus. J Autoimmun 7:763–773
Miyagawa H, Yamai M, Sakaguchi D, Kiyohara C, Tsukamoto H, Kimoto Y et al (2008) Association of polymorphisms in complement C3 gene with susceptibility to systemic lupus erythematosus. Rheumatology 47:158–164
Teutsch SM, Booth DR, Bennetts BH, Heard RN, Stewart GJ (2004) Association of common T cell activation gene polymorphisms with multiple sclerosis in Australian patients. J Neuroimmunol 148:218–230
Tan PL, Borman GB, Wigley RD (1981) Testing clinical criteria for systemic lupus erythematosus in other connective tissue disorders. Rheumatol Int 1:147–149
Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 16:1215
The U.S. National library of medicine and the Nationals institutes of Health. CD28 SNP, Homo sapiens. Retrieved 2 April 2010, www.ncbi.nlm.nih.gov
Brambila-Tapia AJ, Gámez-Nava JI, Salazar-Páramo M, Muñoz-Valle JF, González-López L, Llamas-Covarrubias MA, et al (2010) Increased CD28 serum levels are not associated with specific clinical activity in systemic lupus erythematosus. Rhematol Int Apr 14
Lin CJ, Tam RC (2001) Transcriptional regulation of CD28 expression by CD28GR, a novel promoter element located in exon 1 of the CD28 gene. J Immunol 166:6134–6143
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brambila-Tapia, A.J.L., Dávalos-Rodríguez, I.P., Gámez-Nava, J.I. et al. CD28 proximal promoter polymorphisms in systemic lupus erythematosus susceptibility. Rheumatol Int 32, 2165–2168 (2012). https://doi.org/10.1007/s00296-011-1942-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-011-1942-7